Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.59 |
| ▸ | NOS3 | P29474 | 1/20 | 0.58 |
| ▸ | NOS1 | P29475 | 1/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.49 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | VHL | P40337 | 1/20 | 0.47 |
| ▸ | ELOC | Q15369 | 1/20 | 0.47 |
| ▸ | ELOB | Q15370 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7627846 | 0.86 | MAPT (0.62) | MAPTGAAHDAC1HDAC6NOS3 | |
| SCHEMBL22181781 | 0.84 | CA12 (0.71) | MAPTGAAHDAC1HDAC6NOS3 | |
| SCHEMBL14987117 | 0.84 | HTT (0.63) | MAPTGAAHDAC1HDAC6NOS3 | |
| SCHEMBL3397894 | 0.82 | GAA (0.67) | MAPTGAAHDAC1HDAC6NOS3 | |
| SCHEMBL301503 | 0.82 | GAA (0.62) | MAPTGAAHDAC1HDAC6NOS3 | |
| SCHEMBL17221602 | 0.82 | MAPT (0.62) | MAPTGAAHDAC1HDAC6NOS3 | |
| SCHEMBL324202 | 0.82 | MAPT (0.61) | MAPTGAAHDAC1HDAC6NOS3 | |
| SCHEMBL3316475 | 0.81 | MAPT (0.60) | MAPTGAAHDAC1HDAC6NOS3 | |
| SCHEMBL3521224 | 0.81 | MAPT (0.60) | MAPTGAAHDAC1HDAC6NOS3 | |
| SCHEMBL12321326 | 0.81 | MAPT (0.60) | MAPTGAAHDAC1HDAC6NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226106-A1 | INHIBITORS OF PLASMA KALLIKREIN | SHIRE HUMAN GENETIC THERAPIES (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240226106-A1 | INHIBITORS OF PLASMA KALLIKREIN | SHIRE HUMAN GENETIC THERAPIES (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240226106-A1 | INHIBITORS OF PLASMA KALLIKREIN | SHIRE HUMAN GENETIC THERAPIES (US) | 2024-07-11 | — | — | US | disclosed |
| WO-2024059186-A1 | N-((ISOQUINOLIN-6-YL)METHYL)-1H-PYRAZOLE-4-CARBOXAMID DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS FOR THE TREATMENT OF HEREDITARY ANGIOEDEMA | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-03-21 | — | — | WO | disclosed |
| EP-4308229-A1 | INHIBITORS OF PLASMA KALLIKREIN | Takeda Pharmaceutical Company Limited (JP) | 2024-01-24 | — | — | EP | disclosed |
| CN-117396469-A | Inhibitors of plasma kallikrein | 武田药品工业株式会社 | 2024-01-12 | — | — | CN | disclosed |
| WO-2022197763-A1 | INHIBITORS OF PLASMA KALLIKREIN | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| EP-3305778-B1 | INHIBITORS OF PLASMA KALLIKREIN | KALVISTA PHARMACEUTICALS LTD (GB) | 2022-01-19 | — | — | EP | disclosed |
| CN-106061480-B | Therapeutic inhibitory compounds | 莱福斯希医药公司 | 2020-02-28 | — | — | CN | disclosed |
| CN-105452240-B | Hete rocyclic derivatives | 卡尔维斯塔制药有限公司 | 2018-06-26 | — | — | CN | disclosed |
| WO-2015171526-A2 | TRICYCLIC PYRAZOLOPYRIDINE COMPOUNDS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2015-11-12 | — | — | WO | disclosed |
| WO-2015171526-A2 | TRICYCLIC PYRAZOLOPYRIDINE COMPOUNDS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2015-11-12 | — | — | WO | disclosed |
| US-20150315198-A1 | PYRAZOLOPYRIDINE PYRAZOLOPYRIMIDINE AND RELATED COMPOUNDS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2015-11-05 | — | — | US | disclosed |
| US-20150315198-A1 | PYRAZOLOPYRIDINE PYRAZOLOPYRIMIDINE AND RELATED COMPOUNDS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2015-11-05 | — | — | US | disclosed |
| US-20150315198-A1 | PYRAZOLOPYRIDINE PYRAZOLOPYRIMIDINE AND RELATED COMPOUNDS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2015-11-05 | — | — | US | disclosed |
| WO-2015103317-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | LIFESCI PHARMACEUTICALS, INC. (BB) | 2015-07-09 | — | — | WO | disclosed |
| WO-2015103317-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | LIFESCI PHARMACEUTICALS, INC. (BB) | 2015-07-09 | — | — | WO | disclosed |
| WO-2014188211-A1 | HETEROCYCLIC DERIVATES | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2014-11-27 | — | — | WO | disclosed |
| WO-2014114186-A1 | JNK INHIBITORS | 山东亨利医药科技有限责任公司 (CN) | 2014-07-31 | — | — | WO | disclosed |
| WO-2009095394-A1 | DIAZEPANES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC NEUROSCIENCES GMBH (DE) | 2009-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150315198-A1 | PYRAZOLOPYRIDINE PYRAZOLOPYRIMIDINE AND RELATED COMPOUNDS | TPMT, DPYD, XDH | MAPT 44/4885GAA 2361/4885HDAC1 2409/4885 |
| US-20240226106-A1 | INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK5, KLK1 | MAPT 3389/4885GAA 1946/4885HDAC1 1752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.